A case of lupus nephritis in a patient with chronic HCV A 72-year-old Japanese woman with a 40-year history of lupus nephritis presented with leg edema that had lasted for several weeks. A 72-year-old ...

Nephrotic Syndrome is a group of symptoms that, together, indicate that your kidneys are not working as well as they should. Lupus Nephritis (LN) is the term used when lupus causes inflammation in ...

In a small study, proteinuria improved even in patients with nephrotic syndrome and lupus nephritis. Belimumab appears similarly effective and well tolerated in patients with lupus nephritis (LN) with ...

Significant proteinuria is the hallmark of glomerular disease. With the presentation of proteinuria that is > 3.5 g/day, hypoalbuminemia, edema, and hypercholesterolemia, one must investigate for ...

Objective: To develop better therapy mode and reduce the rate of relapse of nephrotic syndrome in children with steroid sensitive nephrotic syndrome (SSNS). Methods: Compared the effect of 2-month ...

In three patients with typical lipoid nephrosis studied at the onset of their renal disorder, chronic sclerosing glomerulonephritis eventually developed over periods varying from one to 17 years. One ...

DelveInsight's comprehensive analysis reveals the Nephrotic Syndrome therapeutics market reached USD 401 million in 2022 across the 7MM, with emerging therapies including FDA-approved Furoscix and ...

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that its Phase III INShore study evaluating Gazyva (obinutuzumab) in children and young adults aged 2 to 25 years with idiopathic ...

THE nephrotic syndrome has been reported to occur in the course of therapy with a number of drugs including trimethadione, 1, 2 paramethadione, 3 mercurial diuretics, 4 tolbutamide 5 and perchlorate, ...

– Gazyva versus mycophenolate mofetil shows significantly more children and young adults achieved sustained complete remission at week 52 – – If approved, Gazyva could help children and young adults ...

Roche announced statistically significant and clinically meaningful results from the phase III INShore study of Gazyva/Gazyvaro (obinutuzumab) in children and young adults (aged >= 2-25 years) with ...